{"id":9401,"date":"2025-09-02T14:36:59","date_gmt":"2025-09-02T12:36:59","guid":{"rendered":"https:\/\/www.api.parlonsfinance.fr\/?p=9401"},"modified":"2025-09-03T12:34:37","modified_gmt":"2025-09-03T10:34:37","slug":"novo-nordisk-du-sommet-boursier-a-la-tourmente","status":"publish","type":"post","link":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/","title":{"rendered":"Novo Nordisk du sommet boursier \u00e0 la tourmente"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">650 Mds $ de valorisation boursi\u00e8re en 2024, \u201360 % en moins d\u2019un an : Novo Nordisk victime de sp\u00e9culation\u2026 ou d\u2019une vraie d\u00e9gradation de ses fondamentaux ?\u2028<\/h2>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"848\" height=\"342\" src=\"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/unnamed-3.jpg\" alt=\"\" class=\"wp-image-9429\" srcset=\"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/unnamed-3.jpg 848w, https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/unnamed-3-300x121.jpg 300w, https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/unnamed-3-768x310.jpg 768w, https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/unnamed-3-585x236.jpg 585w\" sizes=\"auto, (max-width: 848px) 100vw, 848px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Pour comprendre cette baisse, il faut s&rsquo;int\u00e9resser au march\u00e9 du traitement contre l&rsquo;ob\u00e9sit\u00e9, principal moteur de la valorisation de Novo.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Deux r\u00e9visions successives \u00e0 la baisse des pr\u00e9visions de r\u00e9sultats pour 2025, ce qui a fortement r\u00e9duit la confiance des investisseurs.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Annonce du d\u00e9part anticip\u00e9 du CEO Lars Fruergaard J\u00f8rgensen le 16 mai 2025<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Concurrence accrue d\u2019Eli Lilly, dont le traitement contre l\u2019ob\u00e9sit\u00e9 d\u00e9passe d\u00e9sormais celui de Novo en prescriptions aux \u00c9tats-Unis, faisant craindre une perte de terrain pour le g\u00e9ant danois.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Novo est confront\u00e9 \u00e0 des contrefa\u00e7ons de Wegovy, fabriqu\u00e9es \u00e0 partir de versions m\u00e9lang\u00e9es ou recompos\u00e9es en pharmacie<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Malgr\u00e9 ces freins :\u2028<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Novo Nordisk reste un leader du traitement de l\u2019ob\u00e9sit\u00e9 et a enregistr\u00e9 une croissance solide de +18 % de ses ventes au premier semestre 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Goldman Sachs estime depuis plusieurs mois que la r\u00e9action des investisseurs est exag\u00e9r\u00e9e et a \u00e9mis des recommandations d\u2019achat, tout en r\u00e9duisant ses pr\u00e9visions de hausse, jugeant que la reprise prendra plus de temps que pr\u00e9vu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La guerre de l\u2019innovation pour proposer le traitement anti-ob\u00e9sit\u00e9 le plus efficace d\u00e9terminera le futur leader mondial. Si Novo parvient \u00e0 s\u2019imposer durablement sur ce march\u00e9 estim\u00e9 \u00e0 130 Mds $ d\u2019ici 2030 (Goldman Sachs), son titre pourrait retrouver une trajectoire de hausse.<br>\u2028<br>Selon vous, Novo Nordisk r\u00e9ussira-t-il \u00e0 conserver son avance face \u00e0 la concurrence grandissante d\u2019Eli Lilly ?<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sources : <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>World Health Organization (OMS)<\/strong> sur l\u2019ob\u00e9sit\u00e9 : <a href=\"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight?utm_source=chatgpt.com\">https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight<\/a><\/li>\n\n\n\n<li><strong>FDA (Food &amp; Drug Administration)<\/strong> pour les autorisations de traitements : <a>https:\/\/www.fda.gov\/drugs<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>650 Mds $ de valorisation boursi\u00e8re en 2024, \u201360 % en moins d\u2019un an : Novo Nordisk victime de sp\u00e9culation\u2026 ou d\u2019une vraie d\u00e9gradation de ses fondamentaux ?\u2028 Pour comprendre cette baisse, il faut s&rsquo;int\u00e9resser au march\u00e9 du traitement contre l&rsquo;ob\u00e9sit\u00e9, principal moteur de la valorisation de Novo. Malgr\u00e9 ces freins :\u2028 Novo Nordisk reste [&hellip;]<\/p>\n","protected":false},"author":83,"featured_media":9428,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[793,29,4],"tags":[72,7,5,23,109],"class_list":["post-9401","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-highlighted","category-entreprises","category-nos-analyses","tag-banque","tag-business","tag-finance","tag-investissement","tag-trading"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"650 Mds $ de valorisation boursi\u00e8re en 2024, \u201360 % en moins d\u2019un an : Novo Nordisk victime de sp\u00e9culation\u2026 ou d\u2019une vraie d\u00e9gradation de ses fondamentaux ? Pour comprendre cette baisse, il faut s&#039;int\u00e9resser au march\u00e9 du traitement contre l&#039;ob\u00e9sit\u00e9, principal moteur de la valorisation de Novo. Deux r\u00e9visions successives \u00e0 la baisse des\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Hugo Eberle\"\/>\n\t<meta name=\"google-site-verification\" content=\"LWR9rz0B5_jWJo9zQZbgVIzLEtN8wMZi5qCPMc-5KxU\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.0.1\" \/>\n\n\t\tLWR9rz0B5_jWJo9zQZbgVIzLEtN8wMZi5qCPMc-5KxU\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Parlons Finance - Votre m\u00e9dia financier de r\u00e9f\u00e9rence\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Novo Nordisk du sommet boursier \u00e0 la tourmente\" \/>\n\t\t<meta property=\"og:description\" content=\"650 Mds $ de valorisation boursi\u00e8re en 2024, \u201360 % en moins d\u2019un an : Novo Nordisk victime de sp\u00e9culation\u2026 ou d\u2019une vraie d\u00e9gradation de ses fondamentaux ? Pour comprendre cette baisse, il faut s&#039;int\u00e9resser au march\u00e9 du traitement contre l&#039;ob\u00e9sit\u00e9, principal moteur de la valorisation de Novo. Deux r\u00e9visions successives \u00e0 la baisse des\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/GettyImages-2221165669-dc03c438b75f426884773d34fb719a58-2.jpg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/GettyImages-2221165669-dc03c438b75f426884773d34fb719a58-2.jpg\" \/>\n\t\t<meta property=\"og:image:width\" content=\"1500\" \/>\n\t\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2025-09-02T12:36:59+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-09-03T10:34:37+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/parlonsfinance.be\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:site\" content=\"@parlons_finance\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Novo Nordisk du sommet boursier \u00e0 la tourmente\" \/>\n\t\t<meta name=\"twitter:description\" content=\"650 Mds $ de valorisation boursi\u00e8re en 2024, \u201360 % en moins d\u2019un an : Novo Nordisk victime de sp\u00e9culation\u2026 ou d\u2019une vraie d\u00e9gradation de ses fondamentaux ? Pour comprendre cette baisse, il faut s&#039;int\u00e9resser au march\u00e9 du traitement contre l&#039;ob\u00e9sit\u00e9, principal moteur de la valorisation de Novo. Deux r\u00e9visions successives \u00e0 la baisse des\" \/>\n\t\t<meta name=\"twitter:creator\" content=\"@parlons_finance\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/GettyImages-2221165669-dc03c438b75f426884773d34fb719a58-2.jpg\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/2025\\\/09\\\/02\\\/novo-nordisk-du-sommet-boursier-a-la-tourmente\\\/#blogposting\",\"name\":\"Novo Nordisk du sommet boursier \\u00e0 la tourmente\",\"headline\":\"Novo Nordisk du sommet boursier \\u00e0 la tourmente\",\"author\":{\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/author\\\/hugo-eberle\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/GettyImages-2221165669-dc03c438b75f426884773d34fb719a58-2.jpg\",\"width\":1500,\"height\":1000},\"datePublished\":\"2025-09-02T14:36:59+02:00\",\"dateModified\":\"2025-09-03T12:34:37+02:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/2025\\\/09\\\/02\\\/novo-nordisk-du-sommet-boursier-a-la-tourmente\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/2025\\\/09\\\/02\\\/novo-nordisk-du-sommet-boursier-a-la-tourmente\\\/#webpage\"},\"articleSection\":\"En vedette, Entreprises, Nos analyses, Banque, Business, finance, Investissement, Trading\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/2025\\\/09\\\/02\\\/novo-nordisk-du-sommet-boursier-a-la-tourmente\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.api.parlonsfinance.fr\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/category\\\/nos-analyses\\\/#listItem\",\"name\":\"Nos analyses\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/category\\\/nos-analyses\\\/#listItem\",\"position\":2,\"name\":\"Nos analyses\",\"item\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/category\\\/nos-analyses\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/2025\\\/09\\\/02\\\/novo-nordisk-du-sommet-boursier-a-la-tourmente\\\/#listItem\",\"name\":\"Novo Nordisk du sommet boursier \\u00e0 la tourmente\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/2025\\\/09\\\/02\\\/novo-nordisk-du-sommet-boursier-a-la-tourmente\\\/#listItem\",\"position\":3,\"name\":\"Novo Nordisk du sommet boursier \\u00e0 la tourmente\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/category\\\/nos-analyses\\\/#listItem\",\"name\":\"Nos analyses\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/#organization\",\"name\":\"Parlons Finance\",\"description\":\"Votre m\\u00e9dia financier de r\\u00e9f\\u00e9rence\",\"url\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/\",\"telephone\":\"+32489315298\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/wp-content\\\/uploads\\\/2023\\\/05\\\/logo-pf.jpg\",\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/2025\\\/09\\\/02\\\/novo-nordisk-du-sommet-boursier-a-la-tourmente\\\/#organizationLogo\",\"width\":2048,\"height\":2048},\"image\":{\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/2025\\\/09\\\/02\\\/novo-nordisk-du-sommet-boursier-a-la-tourmente\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/parlonsfinance.be\",\"https:\\\/\\\/twitter.com\\\/parlons_finance\",\"https:\\\/\\\/www.instagram.com\\\/parlonsfinance\\\/?hl=fr\",\"https:\\\/\\\/www.youtube.com\\\/@parlonsfinance8996\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/12997986\\\/admin\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/author\\\/hugo-eberle\\\/#author\",\"url\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/author\\\/hugo-eberle\\\/\",\"name\":\"Hugo Eberle\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/2025\\\/09\\\/02\\\/novo-nordisk-du-sommet-boursier-a-la-tourmente\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f6bad96d990bec52b84633758805de631570b36a463a8deb61febc0721d1931b?s=96&r=g\",\"width\":96,\"height\":96,\"caption\":\"Hugo Eberle\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/2025\\\/09\\\/02\\\/novo-nordisk-du-sommet-boursier-a-la-tourmente\\\/#webpage\",\"url\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/2025\\\/09\\\/02\\\/novo-nordisk-du-sommet-boursier-a-la-tourmente\\\/\",\"name\":\"Novo Nordisk du sommet boursier \\u00e0 la tourmente\",\"description\":\"650 Mds $ de valorisation boursi\\u00e8re en 2024, \\u201360 % en moins d\\u2019un an : Novo Nordisk victime de sp\\u00e9culation\\u2026 ou d\\u2019une vraie d\\u00e9gradation de ses fondamentaux ? Pour comprendre cette baisse, il faut s'int\\u00e9resser au march\\u00e9 du traitement contre l'ob\\u00e9sit\\u00e9, principal moteur de la valorisation de Novo. Deux r\\u00e9visions successives \\u00e0 la baisse des\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/2025\\\/09\\\/02\\\/novo-nordisk-du-sommet-boursier-a-la-tourmente\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/author\\\/hugo-eberle\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/author\\\/hugo-eberle\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/GettyImages-2221165669-dc03c438b75f426884773d34fb719a58-2.jpg\",\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/2025\\\/09\\\/02\\\/novo-nordisk-du-sommet-boursier-a-la-tourmente\\\/#mainImage\",\"width\":1500,\"height\":1000},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/index.php\\\/2025\\\/09\\\/02\\\/novo-nordisk-du-sommet-boursier-a-la-tourmente\\\/#mainImage\"},\"datePublished\":\"2025-09-02T14:36:59+02:00\",\"dateModified\":\"2025-09-03T12:34:37+02:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/\",\"name\":\"Parlons Finance\",\"description\":\"Votre m\\u00e9dia financier de r\\u00e9f\\u00e9rence\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.api.parlonsfinance.fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Novo Nordisk du sommet boursier \u00e0 la tourmente","description":"650 Mds $ de valorisation boursi\u00e8re en 2024, \u201360 % en moins d\u2019un an : Novo Nordisk victime de sp\u00e9culation\u2026 ou d\u2019une vraie d\u00e9gradation de ses fondamentaux ? Pour comprendre cette baisse, il faut s'int\u00e9resser au march\u00e9 du traitement contre l'ob\u00e9sit\u00e9, principal moteur de la valorisation de Novo. Deux r\u00e9visions successives \u00e0 la baisse des","canonical_url":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"google-site-verification":"LWR9rz0B5_jWJo9zQZbgVIzLEtN8wMZi5qCPMc-5KxU","miscellaneous":"LWR9rz0B5_jWJo9zQZbgVIzLEtN8wMZi5qCPMc-5KxU"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/#blogposting","name":"Novo Nordisk du sommet boursier \u00e0 la tourmente","headline":"Novo Nordisk du sommet boursier \u00e0 la tourmente","author":{"@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/author\/hugo-eberle\/#author"},"publisher":{"@id":"https:\/\/www.api.parlonsfinance.fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/GettyImages-2221165669-dc03c438b75f426884773d34fb719a58-2.jpg","width":1500,"height":1000},"datePublished":"2025-09-02T14:36:59+02:00","dateModified":"2025-09-03T12:34:37+02:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/#webpage"},"isPartOf":{"@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/#webpage"},"articleSection":"En vedette, Entreprises, Nos analyses, Banque, Business, finance, Investissement, Trading"},{"@type":"BreadcrumbList","@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.api.parlonsfinance.fr#listItem","position":1,"name":"Home","item":"https:\/\/www.api.parlonsfinance.fr","nextItem":{"@type":"ListItem","@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/category\/nos-analyses\/#listItem","name":"Nos analyses"}},{"@type":"ListItem","@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/category\/nos-analyses\/#listItem","position":2,"name":"Nos analyses","item":"https:\/\/www.api.parlonsfinance.fr\/index.php\/category\/nos-analyses\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/#listItem","name":"Novo Nordisk du sommet boursier \u00e0 la tourmente"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.api.parlonsfinance.fr#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/#listItem","position":3,"name":"Novo Nordisk du sommet boursier \u00e0 la tourmente","previousItem":{"@type":"ListItem","@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/category\/nos-analyses\/#listItem","name":"Nos analyses"}}]},{"@type":"Organization","@id":"https:\/\/www.api.parlonsfinance.fr\/#organization","name":"Parlons Finance","description":"Votre m\u00e9dia financier de r\u00e9f\u00e9rence","url":"https:\/\/www.api.parlonsfinance.fr\/","telephone":"+32489315298","logo":{"@type":"ImageObject","url":"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2023\/05\/logo-pf.jpg","@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/#organizationLogo","width":2048,"height":2048},"image":{"@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/#organizationLogo"},"sameAs":["https:\/\/www.facebook.com\/parlonsfinance.be","https:\/\/twitter.com\/parlons_finance","https:\/\/www.instagram.com\/parlonsfinance\/?hl=fr","https:\/\/www.youtube.com\/@parlonsfinance8996","https:\/\/www.linkedin.com\/company\/12997986\/admin\/"]},{"@type":"Person","@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/author\/hugo-eberle\/#author","url":"https:\/\/www.api.parlonsfinance.fr\/index.php\/author\/hugo-eberle\/","name":"Hugo Eberle","image":{"@type":"ImageObject","@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/f6bad96d990bec52b84633758805de631570b36a463a8deb61febc0721d1931b?s=96&r=g","width":96,"height":96,"caption":"Hugo Eberle"}},{"@type":"WebPage","@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/#webpage","url":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/","name":"Novo Nordisk du sommet boursier \u00e0 la tourmente","description":"650 Mds $ de valorisation boursi\u00e8re en 2024, \u201360 % en moins d\u2019un an : Novo Nordisk victime de sp\u00e9culation\u2026 ou d\u2019une vraie d\u00e9gradation de ses fondamentaux ? Pour comprendre cette baisse, il faut s'int\u00e9resser au march\u00e9 du traitement contre l'ob\u00e9sit\u00e9, principal moteur de la valorisation de Novo. Deux r\u00e9visions successives \u00e0 la baisse des","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/www.api.parlonsfinance.fr\/#website"},"breadcrumb":{"@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/#breadcrumblist"},"author":{"@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/author\/hugo-eberle\/#author"},"creator":{"@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/author\/hugo-eberle\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/GettyImages-2221165669-dc03c438b75f426884773d34fb719a58-2.jpg","@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/#mainImage","width":1500,"height":1000},"primaryImageOfPage":{"@id":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/#mainImage"},"datePublished":"2025-09-02T14:36:59+02:00","dateModified":"2025-09-03T12:34:37+02:00"},{"@type":"WebSite","@id":"https:\/\/www.api.parlonsfinance.fr\/#website","url":"https:\/\/www.api.parlonsfinance.fr\/","name":"Parlons Finance","description":"Votre m\u00e9dia financier de r\u00e9f\u00e9rence","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/www.api.parlonsfinance.fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"Parlons Finance - Votre m\u00e9dia financier de r\u00e9f\u00e9rence","og:type":"article","og:title":"Novo Nordisk du sommet boursier \u00e0 la tourmente","og:description":"650 Mds $ de valorisation boursi\u00e8re en 2024, \u201360 % en moins d\u2019un an : Novo Nordisk victime de sp\u00e9culation\u2026 ou d\u2019une vraie d\u00e9gradation de ses fondamentaux ? Pour comprendre cette baisse, il faut s'int\u00e9resser au march\u00e9 du traitement contre l'ob\u00e9sit\u00e9, principal moteur de la valorisation de Novo. Deux r\u00e9visions successives \u00e0 la baisse des","og:url":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/","og:image":"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/GettyImages-2221165669-dc03c438b75f426884773d34fb719a58-2.jpg","og:image:secure_url":"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/GettyImages-2221165669-dc03c438b75f426884773d34fb719a58-2.jpg","og:image:width":1500,"og:image:height":1000,"article:published_time":"2025-09-02T12:36:59+00:00","article:modified_time":"2025-09-03T10:34:37+00:00","article:publisher":"https:\/\/www.facebook.com\/parlonsfinance.be","twitter:card":"summary_large_image","twitter:site":"@parlons_finance","twitter:title":"Novo Nordisk du sommet boursier \u00e0 la tourmente","twitter:description":"650 Mds $ de valorisation boursi\u00e8re en 2024, \u201360 % en moins d\u2019un an : Novo Nordisk victime de sp\u00e9culation\u2026 ou d\u2019une vraie d\u00e9gradation de ses fondamentaux ? Pour comprendre cette baisse, il faut s'int\u00e9resser au march\u00e9 du traitement contre l'ob\u00e9sit\u00e9, principal moteur de la valorisation de Novo. Deux r\u00e9visions successives \u00e0 la baisse des","twitter:creator":"@parlons_finance","twitter:image":"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/GettyImages-2221165669-dc03c438b75f426884773d34fb719a58-2.jpg"},"aioseo_meta_data":{"post_id":"9401","title":"#post_title","description":null,"keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":"#post_title","og_description":"#post_excerpt","og_object_type":"default","og_image_type":"custom_image","og_image_url":"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/GettyImages-2221165669-dc03c438b75f426884773d34fb719a58-2.jpg","og_image_width":"1500","og_image_height":"1000","og_image_custom_url":"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/GettyImages-2221165669-dc03c438b75f426884773d34fb719a58-2.jpg","og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"custom_image","twitter_image_url":"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/GettyImages-2221165669-dc03c438b75f426884773d34fb719a58-2.jpg","twitter_image_custom_url":"https:\/\/www.api.parlonsfinance.fr\/wp-content\/uploads\/2025\/09\/GettyImages-2221165669-dc03c438b75f426884773d34fb719a58-2.jpg","twitter_image_custom_fields":null,"twitter_title":"#post_title","twitter_description":"#post_excerpt","schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":{"faqs":[],"keyPoints":[],"titles":[],"descriptions":[],"socialPosts":{"email":[],"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"created":"2025-08-31 18:34:24","updated":"2025-09-03 10:40:20","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.api.parlonsfinance.fr\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.api.parlonsfinance.fr\/index.php\/category\/nos-analyses\/\" title=\"Nos analyses\">Nos analyses<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tNovo Nordisk du sommet boursier \u00e0 la tourmente\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.api.parlonsfinance.fr"},{"label":"Nos analyses","link":"https:\/\/www.api.parlonsfinance.fr\/index.php\/category\/nos-analyses\/"},{"label":"Novo Nordisk du sommet boursier \u00e0 la tourmente","link":"https:\/\/www.api.parlonsfinance.fr\/index.php\/2025\/09\/02\/novo-nordisk-du-sommet-boursier-a-la-tourmente\/"}],"_links":{"self":[{"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/posts\/9401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/users\/83"}],"replies":[{"embeddable":true,"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/comments?post=9401"}],"version-history":[{"count":5,"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/posts\/9401\/revisions"}],"predecessor-version":[{"id":9441,"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/posts\/9401\/revisions\/9441"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/media\/9428"}],"wp:attachment":[{"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/media?parent=9401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/categories?post=9401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.api.parlonsfinance.fr\/index.php\/wp-json\/wp\/v2\/tags?post=9401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}